Patents Assigned to Flanders Interuniversity Institute for Biotechnology
-
Patent number: 9078895Abstract: It has now been found that the p53 pathway is inactivated in ocular cancers such as retinoblastoma. As such, the present invention is a method for inducing ocular cancer cell death using a p53 activator. In particular embodiments, the p53 activator blocks the interaction between DM2 or DMX and p53. As the p53 activator induces ocular cancer cell death, a method for preventing or treating ocular cancer is also provided.Type: GrantFiled: December 5, 2013Date of Patent: July 14, 2015Assignees: St. Jude Children's Research Hospital, Flanders Interuniversity Institute for Biotechnology, Universiteit Gent, Leiden University Medical CenterInventors: Michael A. Dyer, Jean-Christophe Marine, Aart Gerrit Jochemsen
-
Publication number: 20140121218Abstract: It has now been found that the p53 pathway is inactivated in ocular cancers such as retinoblastoma. As such, the present invention is a method for inducing ocular cancer cell death using a p53 activator. In particular embodiments, the p53 activator blocks the interaction between DM2 or DMX and p53. As the p53 activator induces ocular cancer cell death, a method for preventing or treating ocular cancer is also provided.Type: ApplicationFiled: December 5, 2013Publication date: May 1, 2014Applicants: St. Jude Children's Research Hospital, Leiden University Medical Center, Universiteit Gent, Flanders Interuniversity Institute for Biotechnology VIBInventors: Michael A. Dyer, Jean-Christopher Marine, Aart Gerrit Jochemsen
-
Patent number: 8614192Abstract: It has now been found that the p53 pathway is inactivated in ocular cancers such as retinoblastoma. As such, the present invention is a method for inducing ocular cancer cell death using a p53 activator. In particular embodiments, the p53 activator blocks the interaction between DM2 or DMX and p53. As the p53 activator induces ocular cancer cell death, a method for preventing or treating ocular cancer is also provided.Type: GrantFiled: July 24, 2007Date of Patent: December 24, 2013Assignees: Leiden University Medical Center, Flanders Interuniversity Institute for Biotechnology, VIB, St. Jude Children's Research HospitalInventors: Michael A. Dyer, Jean-Christophe Marine, Aart Gerrit Jochemsen
-
Patent number: 7727971Abstract: The present invention relates to prevention and treatment of strokes and ischemic diseases and to post-ischemic therapeutic treatment. The invention furthermore relates to the use of a growth factor or nucleic acids ensuring increased expression of a growth factor for treating, more particularly restoring the function of ischemic tissue, in particular muscles such as myocardium and skeletal muscles.Type: GrantFiled: June 21, 2006Date of Patent: June 1, 2010Assignees: Life Sciences Research Partners VZW, Flanders Interuniversity Institute for Biotechnology (VIB)Inventors: Peter Carmeliet, Désiré Collen
-
Patent number: 7709450Abstract: VEGF-B is shown to be needed for cardiac muscle revascularization after heart infarction, and methods of promoting or stimulating vascular development, e.g. angiogenesis and/or arteriogenesis, particularly in ischemic mammals, are disclosed.Type: GrantFiled: June 20, 2002Date of Patent: May 4, 2010Assignees: Ludwig Institute for Cancer Research, Flanders Interuniversity Institute for BiotechnologyInventors: Ulf Eriksson, Xuri Li, Peter Carmeliet, Desire Collen
-
Publication number: 20080009037Abstract: The present invention provides genetically engineered strains of methylotrophic yeast including Pichia and especially Pichia pastoris capable of producing proteins with reduced or modified glycosylation. Methods of producing glycoproteins with reduced and/or modified glycosylation using such genetically engineered strains of Pichia are also provided. Vectors, which comprise coding sequences for ?-1,2-mannosidase I, glucosidase II, GlcNAc-tranferase I and mannosidase II or comprising OCH1 disrupting sequence, for transforming methylotrophic yeasts are contemplated by the present invention. Kit for providing the comtemplated vectors are also included in this invention.Type: ApplicationFiled: July 13, 2007Publication date: January 10, 2008Applicant: Flanders Interuniversity Institute For BiotechnologyInventors: Roland Contreras, Nico Callewaert, Steven Geysens, Vladimir Kaigorodov, Vervecken Wouter
-
Patent number: 7252933Abstract: The present invention provides genetically engineered strains of methylotrophic yeast including Pichia and especially Pichia pastoris capable of producing proteins with reduced or modified glycosylation. Methods of producing glycoproteins with reduced and/or modified glycosylation using such genetically engineered strains of Pichia are also provided. Vectors, which comprise coding sequences for ?-1,2-mannosidase I, glucosidase II, GlcNAc-tranferase I and mannosidase II or comprising OCH1 disrupting sequence, for transforming methylotrophic yeasts are contemplated by the present invention. Kit for providing the comtemplated vectors are also included in this invention.Type: GrantFiled: June 26, 2002Date of Patent: August 7, 2007Assignee: Flanders Interuniversity Institute for BiotechnologyInventors: Roland Contreras, Nico L. M. Callewaert, Steven C. J. Geysens, Vladimir Kaigorodov, Vervecken Wouter
-
Patent number: 6930089Abstract: Vascular endothelial growth factor, placenta growth factor or combinations of both including heteodimers are useful in the treatment or prevention of stroke or ischemic diseases in mammals.Type: GrantFiled: February 5, 2001Date of Patent: August 16, 2005Assignees: D. Collen Research Foundation vzw, Flanders Interuniversity Institute for Biotechnology, VIBInventor: Peter Carmeliet
-
Patent number: 6803225Abstract: The present invention provides genetically engineered strains of Pichia capable of producing proteins with reduced glycosylation. In particular, the genetically engineered strains of the present invention are capable of expressing either or both of an (&agr;-1,2-mannosidase and glucosidase II. The genetically engineered strains of the present invention can be further modified such that the OCH1 gene is disrupted. Methods of producing glycoproteins with reduced glycosylation using such genetically engineered stains of Pichia are also provided.Type: GrantFiled: June 29, 2001Date of Patent: October 12, 2004Assignee: Flanders Interuniversity Institute for BiotechnologyInventors: Roland Contreras, Nico L. M. Callewaert, Steven C. J. Geysens
-
Publication number: 20020188109Abstract: The present invention provides genetically engineered strains of Pichia capable of producing proteins with reduced glycosylation. In particular, the genetically engineered strains of the present invention are capable of expressing either or both of an (&agr;-1,2-mannosidase and glucosidase II. The genetically engineered strains of the present invention can be further modified such that the OCH1 gene is disrupted. Methods of producing glycoproteins with reduced glycosylation using such genetically engineered stains of Pichia are also provided.Type: ApplicationFiled: June 29, 2001Publication date: December 12, 2002Applicant: FLANDERS INTERUNIVERSITY INSTITUTE FOR BIOTECHNOLOGYInventors: Roland Contreras, Nico L. M. Callewaert, Steven C. J. Geysens